U.S. near bottom of wealthy nations in childbirth deaths November 22, 2015
American children with autism may have been undercounted November 14, 2015
Medicare to spend $9 billion on hepatitis C drugs November 14, 2015
What happens after you down an energy drink? November 14, 2015
U.S. adult cigarette smoking hits a new low November 13, 2015
U.S. sees alarming jump in newborns with syphilis November 12, 2015
DNA hunt on as Chipotle E. coli outbreak grows November 3, 2015
Experts urge reassessment of breast cancer screening November 1, 2015
At top hospital, almost half of surgeries have drug mishap October 30, 2015
Study: Want a younger brain? Eat fish, stay away from meat October 25, 2015
The drug, Vizamyl, is an injection of radioactive material designed to highlight abnormal brain plaque in medical imaging scans.
Dementia caused by Alzheimer's is associated with buildup of the plaque, known as beta amyloid protein. However, it can also be found in patients who do not have neurological problems.
Vizamyl works by binding to the plaque and creating images that show up on positron emission tomography, or PET, scans of the brain.
A negative scan means there is little plaque and the cause of dementia is probably not Alzheimer's, according to an FDA release. A positive scan means the patient has at least some plaque, but does not mean they definitely have Alzheimer's. The injection is intended as one tool to help physicians identify the cause of patient's cognitive decline.
Doctors currently diagnose Alzheimer's disease by observing patients and administering physical and mental tests. The disease is the sixth-leading cause of death in the U.S. and the most common form of dementia, a term for brain disorders that affect memory, judgment and other mental functions.
The Centers for Disease Control and Prevention estimates that Alzheimer's affects 5 million elderly Americans. The agency says that figure may triple in coming years as the baby boom generation ages, unless more effective ways are found to prevent the disease.
Alzheimer's attacks neurons in the brain, leading to problems with memory, thinking and behavior. There is no cure for the disease, and scientists are not even sure what causes it.
Vizamyl is manufactured for General Electric Co.'s GE Healthcare division by Medi-Physics Inc., based in Arlington Heights, Ill. It is the second drug FDA has approved to help screen for Alzheimer's in the last two years. The FDA approved a similar drug called Amyvid from Eli Lilly & Co. in April 2012.
More Nation & World Headlines
Protesters to target Chicago shopping on Black Friday Americans hit the road for Thanksgiving President Obama pardons a pair of turkeys Signed editions of Harper Lee novel offered for $1,500 U.S. suspends personnel over botched Afghan attack Russia sends air-defense missiles to Turkey Casey Kasemís widow sued for wrongful death Can a five-hour Alaskan train ride be compelling Thanksgiving viewing?
Our new comment system is not supported in IE 7. Please upgrade your browser here.